CA 15-3
CA 15-3 is a tumor marker protein that can be elevated in breast cancer and used for monitoring treatment.
CA 15-3
Normal range
Normal range
<32.4 u/ml
<32.4 u/ml
Normal range
<32.4 u/ml
<32.4 u/ml
Normal range
CA 15-3
CA 15-3
CA 15-3 is a tumor marker protein that can be elevated in breast cancer and used for monitoring treatment.
CA 15-3
Normal range
<32.4 u/ml
Normal range
<32.4 u/ml
<32.4 u/ml
Normal range
CA 15-3
CA 15-3
CA 15-3 is a tumor marker protein that can be elevated in breast cancer and used for monitoring treatment.
CA 15-3
Normal range
<32.4 u/ml
Normal range
<32.4 u/ml
<32.4 u/ml
Normal range
CA 15-3
CA 15-3
CA 15-3 is a tumor marker protein that can be elevated in breast cancer and used for monitoring treatment.
CA 15-3
Normal range
<32.4 u/ml
Normal range
<32.4 u/ml
<32.4 u/ml
Normal range
CA 15-3
Dr. Daniel McNally
MBBS
Your Breast Health Monitoring System
Your Breast Health Monitoring System
Your Breast Health Monitoring System
Your breast cells produce a protein called CA 15-3 (Cancer Antigen 15-3), which normally exists at very low levels in healthy individuals. Healthy cells in the breast release a protein called CA 15-3, but when breast tissue becomes cancerous or stressed, these cells can produce significantly more of this protein, causing levels to rise in your bloodstream. CA 15-3 serves as your body's molecular messenger, providing valuable insights about breast health and helping healthcare providers monitor treatment responses and detect cancer recurrence.
CA15-3 is a non-invasive test for monitoring and prediction of breast cancer, making it useful for tracking how well treatments are working and whether cancer has returned after initial therapy.
Your breast cells produce a protein called CA 15-3 (Cancer Antigen 15-3), which normally exists at very low levels in healthy individuals. Healthy cells in the breast release a protein called CA 15-3, but when breast tissue becomes cancerous or stressed, these cells can produce significantly more of this protein, causing levels to rise in your bloodstream. CA 15-3 serves as your body's molecular messenger, providing valuable insights about breast health and helping healthcare providers monitor treatment responses and detect cancer recurrence.
CA15-3 is a non-invasive test for monitoring and prediction of breast cancer, making it useful for tracking how well treatments are working and whether cancer has returned after initial therapy.
When CA 15-3 Levels Rise: Understanding Your Body's Signals
When CA 15-3 Levels Rise: Understanding Your Body's Signals
When CA 15-3 Levels Rise: Understanding Your Body's Signals
When CA 15-3 Levels Rise: Understanding Your Body's Signals
Discover how elevated CA 15-3 can indicate breast cancer progression and what this means.
Read more
The Role of CA 15-3 in Breast Cancer Care
The Role of CA 15-3 in Breast Cancer Care
The Role of CA 15-3 in Breast Cancer Care
The Role of CA 15-3 in Breast Cancer Care
Learn why this protein marker is essential for monitoring treatment responses and detecting cancer recurrence in breast cancer patients.
Read more
What Influences Your CA 15-3 Levels
What Influences Your CA 15-3 Levels
What Influences Your CA 15-3 Levels
What Influences Your CA 15-3 Levels
Understanding the various factors that can affect your CA 15-3 levels, from cancer progression to benign conditions.
Read more
Understanding Your Results
Understanding Your Results
Understanding Your Results
Understanding Your Results
Decode your numbers and understand exactly what your CA 15-3 levels mean for your breast health and ongoing care.
Read more
When CA 15-3 Levels Rise: Understanding Your Body's Signals
In general, concentrations of CA 15-3 are directly correlated to how large a breast cancer might be, making this marker particularly valuable for understanding disease progression. Increasing CA 15-3 levels may suggest the cancer has grown or recurred, while decreasing levels may indicate the cancer is getting smaller.
Most people with early-stage breast cancer have normal CA 15-3 levels. However, levels typically rise as breast cancer advances. This can make CA 15-3 useful for monitoring how cancer responds to treatment—successful therapy typically causes levels to decrease, whilst treatment resistance or cancer progression leads to rising levels.
When CA 15-3 Levels Rise: Understanding Your Body's Signals
In general, concentrations of CA 15-3 are directly correlated to how large a breast cancer might be, making this marker particularly valuable for understanding disease progression. Increasing CA 15-3 levels may suggest the cancer has grown or recurred, while decreasing levels may indicate the cancer is getting smaller.
Most people with early-stage breast cancer have normal CA 15-3 levels. However, levels typically rise as breast cancer advances. This can make CA 15-3 useful for monitoring how cancer responds to treatment—successful therapy typically causes levels to decrease, whilst treatment resistance or cancer progression leads to rising levels.
When CA 15-3 Levels Rise: Understanding Your Body's Signals
In general, concentrations of CA 15-3 are directly correlated to how large a breast cancer might be, making this marker particularly valuable for understanding disease progression. Increasing CA 15-3 levels may suggest the cancer has grown or recurred, while decreasing levels may indicate the cancer is getting smaller.
Most people with early-stage breast cancer have normal CA 15-3 levels. However, levels typically rise as breast cancer advances. This can make CA 15-3 useful for monitoring how cancer responds to treatment—successful therapy typically causes levels to decrease, whilst treatment resistance or cancer progression leads to rising levels.
When CA 15-3 Levels Rise: Understanding Your Body's Signals
In general, concentrations of CA 15-3 are directly correlated to how large a breast cancer might be, making this marker particularly valuable for understanding disease progression. Increasing CA 15-3 levels may suggest the cancer has grown or recurred, while decreasing levels may indicate the cancer is getting smaller.
Most people with early-stage breast cancer have normal CA 15-3 levels. However, levels typically rise as breast cancer advances. This can make CA 15-3 useful for monitoring how cancer responds to treatment—successful therapy typically causes levels to decrease, whilst treatment resistance or cancer progression leads to rising levels.
The Role of CA 15-3 in Breast Cancer Care
Cancer antigen 15.3 (CA 15-3) should only be used to determine response to therapy in patients with metastatic breast cancer or for the early detection of recurrence in patients with previously treated breast cancer. This specific application makes CA 15-3 essential for ongoing breast cancer management rather than initial diagnosis.
CA15.3 is mostly of value for treatment monitoring of breast cancer and is not used in isolation for diagnosis. Healthcare providers use CA 15-3 alongside other clinical assessments, imaging studies, and physical examinations to build a comprehensive picture of your health.
During treatment, CA 15-3 monitoring can help determine whether therapies are working effectively, although it is an imperfect test. For individuals who have completed breast cancer treatment, periodic CA 15-3 testing can help detect recurrence before symptoms develop or imaging studies show visible changes.
The Role of CA 15-3 in Breast Cancer Care
Cancer antigen 15.3 (CA 15-3) should only be used to determine response to therapy in patients with metastatic breast cancer or for the early detection of recurrence in patients with previously treated breast cancer. This specific application makes CA 15-3 essential for ongoing breast cancer management rather than initial diagnosis.
CA15.3 is mostly of value for treatment monitoring of breast cancer and is not used in isolation for diagnosis. Healthcare providers use CA 15-3 alongside other clinical assessments, imaging studies, and physical examinations to build a comprehensive picture of your health.
During treatment, CA 15-3 monitoring can help determine whether therapies are working effectively, although it is an imperfect test. For individuals who have completed breast cancer treatment, periodic CA 15-3 testing can help detect recurrence before symptoms develop or imaging studies show visible changes.
The Role of CA 15-3 in Breast Cancer Care
Cancer antigen 15.3 (CA 15-3) should only be used to determine response to therapy in patients with metastatic breast cancer or for the early detection of recurrence in patients with previously treated breast cancer. This specific application makes CA 15-3 essential for ongoing breast cancer management rather than initial diagnosis.
CA15.3 is mostly of value for treatment monitoring of breast cancer and is not used in isolation for diagnosis. Healthcare providers use CA 15-3 alongside other clinical assessments, imaging studies, and physical examinations to build a comprehensive picture of your health.
During treatment, CA 15-3 monitoring can help determine whether therapies are working effectively, although it is an imperfect test. For individuals who have completed breast cancer treatment, periodic CA 15-3 testing can help detect recurrence before symptoms develop or imaging studies show visible changes.
The Role of CA 15-3 in Breast Cancer Care
Cancer antigen 15.3 (CA 15-3) should only be used to determine response to therapy in patients with metastatic breast cancer or for the early detection of recurrence in patients with previously treated breast cancer. This specific application makes CA 15-3 essential for ongoing breast cancer management rather than initial diagnosis.
CA15.3 is mostly of value for treatment monitoring of breast cancer and is not used in isolation for diagnosis. Healthcare providers use CA 15-3 alongside other clinical assessments, imaging studies, and physical examinations to build a comprehensive picture of your health.
During treatment, CA 15-3 monitoring can help determine whether therapies are working effectively, although it is an imperfect test. For individuals who have completed breast cancer treatment, periodic CA 15-3 testing can help detect recurrence before symptoms develop or imaging studies show visible changes.
What Influences Your CA 15-3 Levels
Breast cancer represents the primary cause of CA 15-3 elevation, particularly in advanced or metastatic disease. In metastatic breast cancer (cancer that has spread to other organs), the highest CA 15-3 levels are typically observed.
Mild to moderate elevations of CA 15-3 are seen in a variety of conditions, including cancer of the lung, pancreas, ovary, prostate, and colon as well as cirrhosis, hepatitis, and benign breast disorders and in a small percentage of healthy individuals. This means that elevated CA 15-3 levels don't automatically indicate breast cancer, particularly when elevations are modest.
Benign breast conditions, including fibrocystic disease, mastitis, or other inflammatory breast conditions, can cause temporary CA 15-3 elevations. Liver diseases such as hepatitis or cirrhosis may also affect CA 15-3 levels, as the liver plays a role in processing and clearing this protein from your bloodstream.
Certain medications, pregnancy, and other physiological conditions can influence CA 15-3 levels, though these effects are typically less pronounced than those seen with cancer. Your healthcare provider will consider your complete medical history and current health status when interpreting CA 15-3 results.
What Influences Your CA 15-3 Levels
Breast cancer represents the primary cause of CA 15-3 elevation, particularly in advanced or metastatic disease. In metastatic breast cancer (cancer that has spread to other organs), the highest CA 15-3 levels are typically observed.
Mild to moderate elevations of CA 15-3 are seen in a variety of conditions, including cancer of the lung, pancreas, ovary, prostate, and colon as well as cirrhosis, hepatitis, and benign breast disorders and in a small percentage of healthy individuals. This means that elevated CA 15-3 levels don't automatically indicate breast cancer, particularly when elevations are modest.
Benign breast conditions, including fibrocystic disease, mastitis, or other inflammatory breast conditions, can cause temporary CA 15-3 elevations. Liver diseases such as hepatitis or cirrhosis may also affect CA 15-3 levels, as the liver plays a role in processing and clearing this protein from your bloodstream.
Certain medications, pregnancy, and other physiological conditions can influence CA 15-3 levels, though these effects are typically less pronounced than those seen with cancer. Your healthcare provider will consider your complete medical history and current health status when interpreting CA 15-3 results.
What Influences Your CA 15-3 Levels
Breast cancer represents the primary cause of CA 15-3 elevation, particularly in advanced or metastatic disease. In metastatic breast cancer (cancer that has spread to other organs), the highest CA 15-3 levels are typically observed.
Mild to moderate elevations of CA 15-3 are seen in a variety of conditions, including cancer of the lung, pancreas, ovary, prostate, and colon as well as cirrhosis, hepatitis, and benign breast disorders and in a small percentage of healthy individuals. This means that elevated CA 15-3 levels don't automatically indicate breast cancer, particularly when elevations are modest.
Benign breast conditions, including fibrocystic disease, mastitis, or other inflammatory breast conditions, can cause temporary CA 15-3 elevations. Liver diseases such as hepatitis or cirrhosis may also affect CA 15-3 levels, as the liver plays a role in processing and clearing this protein from your bloodstream.
Certain medications, pregnancy, and other physiological conditions can influence CA 15-3 levels, though these effects are typically less pronounced than those seen with cancer. Your healthcare provider will consider your complete medical history and current health status when interpreting CA 15-3 results.
What Influences Your CA 15-3 Levels
Breast cancer represents the primary cause of CA 15-3 elevation, particularly in advanced or metastatic disease. In metastatic breast cancer (cancer that has spread to other organs), the highest CA 15-3 levels are typically observed.
Mild to moderate elevations of CA 15-3 are seen in a variety of conditions, including cancer of the lung, pancreas, ovary, prostate, and colon as well as cirrhosis, hepatitis, and benign breast disorders and in a small percentage of healthy individuals. This means that elevated CA 15-3 levels don't automatically indicate breast cancer, particularly when elevations are modest.
Benign breast conditions, including fibrocystic disease, mastitis, or other inflammatory breast conditions, can cause temporary CA 15-3 elevations. Liver diseases such as hepatitis or cirrhosis may also affect CA 15-3 levels, as the liver plays a role in processing and clearing this protein from your bloodstream.
Certain medications, pregnancy, and other physiological conditions can influence CA 15-3 levels, though these effects are typically less pronounced than those seen with cancer. Your healthcare provider will consider your complete medical history and current health status when interpreting CA 15-3 results.
Understanding Your Results
Reference Ranges:
Normal levels: <30 U/mL
Normal CA 15-3 levels in individuals is generally reassuring, however it is important to note CA 15-3 is not a screening test and can be low or negative even when cancer is present. If you have symptoms or concerns, a thorough assessment alongside examination with your healthcare provider is important.
Elevated levels may indicate benign breast conditions, cancer in some situations, or other health conditions affecting CA 15-3 production. Your healthcare provider will consider your medical history, symptoms, and other diagnostic tests to determine the most appropriate next steps.
Understanding Your Results
Reference Ranges:
Normal levels: <30 U/mL
Normal CA 15-3 levels in individuals is generally reassuring, however it is important to note CA 15-3 is not a screening test and can be low or negative even when cancer is present. If you have symptoms or concerns, a thorough assessment alongside examination with your healthcare provider is important.
Elevated levels may indicate benign breast conditions, cancer in some situations, or other health conditions affecting CA 15-3 production. Your healthcare provider will consider your medical history, symptoms, and other diagnostic tests to determine the most appropriate next steps.
Understanding Your Results
Reference Ranges:
Normal levels: <30 U/mL
Normal CA 15-3 levels in individuals is generally reassuring, however it is important to note CA 15-3 is not a screening test and can be low or negative even when cancer is present. If you have symptoms or concerns, a thorough assessment alongside examination with your healthcare provider is important.
Elevated levels may indicate benign breast conditions, cancer in some situations, or other health conditions affecting CA 15-3 production. Your healthcare provider will consider your medical history, symptoms, and other diagnostic tests to determine the most appropriate next steps.
Understanding Your Results
Reference Ranges:
Normal levels: <30 U/mL
Normal CA 15-3 levels in individuals is generally reassuring, however it is important to note CA 15-3 is not a screening test and can be low or negative even when cancer is present. If you have symptoms or concerns, a thorough assessment alongside examination with your healthcare provider is important.
Elevated levels may indicate benign breast conditions, cancer in some situations, or other health conditions affecting CA 15-3 production. Your healthcare provider will consider your medical history, symptoms, and other diagnostic tests to determine the most appropriate next steps.
The Takeaway
CA 15-3 levels provide crucial information about breast cancer progression and treatment response, serving as a monitoring tool for individuals with advanced breast cancer or those at risk of recurrence. It is not typically used as a screening test, and it is an imperfect test not usually used in isolation, and is usually combined with other testing methods depending on the situation.
CA 15-3 monitoring represents an important component of comprehensive breast cancer care, providing valuable insights that complement physical examinations, imaging studies, and other diagnostic approaches.
The Takeaway
CA 15-3 levels provide crucial information about breast cancer progression and treatment response, serving as a monitoring tool for individuals with advanced breast cancer or those at risk of recurrence. It is not typically used as a screening test, and it is an imperfect test not usually used in isolation, and is usually combined with other testing methods depending on the situation.
CA 15-3 monitoring represents an important component of comprehensive breast cancer care, providing valuable insights that complement physical examinations, imaging studies, and other diagnostic approaches.
The Takeaway
CA 15-3 levels provide crucial information about breast cancer progression and treatment response, serving as a monitoring tool for individuals with advanced breast cancer or those at risk of recurrence. It is not typically used as a screening test, and it is an imperfect test not usually used in isolation, and is usually combined with other testing methods depending on the situation.
CA 15-3 monitoring represents an important component of comprehensive breast cancer care, providing valuable insights that complement physical examinations, imaging studies, and other diagnostic approaches.
The Takeaway
CA 15-3 levels provide crucial information about breast cancer progression and treatment response, serving as a monitoring tool for individuals with advanced breast cancer or those at risk of recurrence. It is not typically used as a screening test, and it is an imperfect test not usually used in isolation, and is usually combined with other testing methods depending on the situation.
CA 15-3 monitoring represents an important component of comprehensive breast cancer care, providing valuable insights that complement physical examinations, imaging studies, and other diagnostic approaches.
References
NHS Gloucestershire Hospitals. (2023). CA 15-3 (Tumour marker). NHS Foundation Trust Clinical Guidelines.
National Institute for Health and Care Excellence. (2021). Advanced breast cancer: diagnosis and treatment. NICE Clinical Guideline CG81.
Royal Liverpool and Broadgreen University Hospitals. (2023). CA 15-3 - Tumour Marker Serum. NHS Trust Laboratory Guidelines.
University Hospitals of North Midlands. (2022). Cancer antigen 15.3. NHS Foundation Trust Pathology Services.
References
NHS Gloucestershire Hospitals. (2023). CA 15-3 (Tumour marker). NHS Foundation Trust Clinical Guidelines.
National Institute for Health and Care Excellence. (2021). Advanced breast cancer: diagnosis and treatment. NICE Clinical Guideline CG81.
Royal Liverpool and Broadgreen University Hospitals. (2023). CA 15-3 - Tumour Marker Serum. NHS Trust Laboratory Guidelines.
University Hospitals of North Midlands. (2022). Cancer antigen 15.3. NHS Foundation Trust Pathology Services.
References
NHS Gloucestershire Hospitals. (2023). CA 15-3 (Tumour marker). NHS Foundation Trust Clinical Guidelines.
National Institute for Health and Care Excellence. (2021). Advanced breast cancer: diagnosis and treatment. NICE Clinical Guideline CG81.
Royal Liverpool and Broadgreen University Hospitals. (2023). CA 15-3 - Tumour Marker Serum. NHS Trust Laboratory Guidelines.
University Hospitals of North Midlands. (2022). Cancer antigen 15.3. NHS Foundation Trust Pathology Services.
References
NHS Gloucestershire Hospitals. (2023). CA 15-3 (Tumour marker). NHS Foundation Trust Clinical Guidelines.
National Institute for Health and Care Excellence. (2021). Advanced breast cancer: diagnosis and treatment. NICE Clinical Guideline CG81.
Royal Liverpool and Broadgreen University Hospitals. (2023). CA 15-3 - Tumour Marker Serum. NHS Trust Laboratory Guidelines.
University Hospitals of North Midlands. (2022). Cancer antigen 15.3. NHS Foundation Trust Pathology Services.
Research articles
Research articles
Research articles
Control your preventive health with Emerald
Subscribe to our newsletter
© 2025 Emerald Labs Ltd
Subscribe to our newsletter
© 2025 Emerald Labs Ltd
Subscribe to our newsletter
© 2025 Emerald Labs Ltd
Subscribe to our newsletter
© 2025 Emerald Labs Ltd
Subscribe to our newsletter
© 2025 Emerald Labs Ltd
Subscribe to our newsletter
© 2025 Emerald Labs Ltd